"Breast cancer (BC) remains the deadliest female malignancy. The surrogate
subtypes displaying (over)expression of the HER2 receptor (HER2+
) display
some of the worse prognosis and survival rates. The incorporation of antiHER2 biologicals in the clinics has dramatically improved HER2+ BC
prognosis. However, most patients treated with the anti-HER2 antibody
trastuzumab eventually relapse due to therapy resistance. The
development of alternative anti-HER2 therapies, namely the combined use
of two HER2-blocking antibodies (trastuzumab and pertuzumab), brought
clinical improvement....)"
